Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 2,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $52.88, for a total value of $105,760.00. Following the completion of the sale, the vice president owned 29,891 shares in the company, valued at approximately $1,580,636.08. This represents a 6.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Friday, June 20th, Patrick Lamy sold 875 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.59, for a total value of $47,766.25.
• On Monday, June 16th, Patrick Lamy sold 2,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.14, for a total transaction of $108,280.00.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total transaction of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.00, for a total value of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Stock Up 0.3%

Shares of AKRO stock opened at $52.01 on Friday. Akero Therapeutics, Inc. has a fifty-two week low of $21.02 and a fifty-two week high of $58.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.80 and a current ratio of 16.80. The firm has a market capitalization of $4.15 billion, a PE ratio of -26.67 and a beta of -0.15. The stock’s 50-day simple moving average is $48.66 and its 200-day simple moving average is $42.57.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $1.91. Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Trading of Akero Therapeutics

Large investors have recently bought and sold shares of the company. Proficio Capital Partners LLC purchased a new stake in shares of Akero Therapeutics during the 4th quarter valued at about $320,000. Charles Schwab Investment Management Inc. grew its position in Akero Therapeutics by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock valued at $15,042,000 after purchasing an additional 8,096 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock valued at $227,000 after purchasing an additional 8,147 shares during the last quarter. Great Lakes Advisors LLC bought a new position in shares of Akero Therapeutics in the fourth quarter worth about $5,380,000. Finally, Swiss National Bank raised its holdings in Akero Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 95,600 shares of the company’s stock valued at $2,660,000 after acquiring an additional 1,100 shares in the last quarter.

Analyst Upgrades and Downgrades

AKRO has been the subject of several recent analyst reports. Citigroup decreased their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Bank of America increased their target price on Akero Therapeutics from $63.00 to $64.00 and gave the stock a “buy” rating in a research report on Tuesday, May 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $82.50.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.